Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
These authors contributed equally to this work.
Euro Surveill. 2021 Apr;26(16). doi: 10.2807/1560-7917.ES.2021.26.16.2100413.
SARS-CoV-2 variants of concern (VOC) should not escape molecular surveillance. We investigated if SARS-CoV-2 rapid antigen tests (RATs) could detect B.1.1.7 and B.1.351 VOCs in certain laboratory conditions. Infectious cell culture supernatants containing B.1.1.7, B.1.351 or non-VOC SARS-CoV-2 were respectively diluted both in DMEM and saliva. Dilutions were analysed with Roche, Siemens, Abbott, nal von minden and RapiGEN RATs. While further studies with appropriate real-life clinical samples are warranted, all RATs detected B.1.1.7 and B.1.351, generally comparable to non-VOC strain.
关注的 SARS-CoV-2 变异株（VOC）不应逃避分子监测。我们研究了 SARS-CoV-2 快速抗原检测（RAT）是否可以在某些实验室条件下检测到 B.1.1.7 和 B.1.351 VOC。分别含有 B.1.1.7、B.1.351 或非 VOC SARS-CoV-2 的感染细胞培养上清液在 DMEM 和唾液中分别进行稀释。罗氏、西门子、雅培、纳尔冯明登和 RapiGEN RAT 对稀释液进行了分析。虽然需要进一步研究适当的现实临床样本，但所有 RAT 均检测到 B.1.1.7 和 B.1.351，通常与非 VOC 株相当。
